Clinical Trial Update: Managed Access Programs for SEG101, Crizanlizumab

View source ↗

Summary

Clinical trial update describing managed access programs for crizanlizumab (SEG101) for sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Crizanlizumab (SEG101) (crizanlizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Disease | Status: AVAILABLE